| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04436510 | HEALEY ALS Platform Trial - Regimen B Verdiperstat | PHASE2 | COMPLETED | 167 | — | — | Jul 28, 2020 | Dec 6, 2022 | Jun 12, 2023 | 1 | United States |
Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.
| Arm | Type | Description |
|---|---|---|
| Verdiperstat | EXPERIMENTAL | Verdiperstat is administered twice daily p.o. for 24 weeks. |
| Matching Placebo | PLACEBO_COMPARATOR | Matching placebo is administered twice daily p.o. for 24 weeks. |
| Name | Type | Description |
|---|---|---|
| Matching Placebo | DRUG | Drug: Matching Placebo Administration: Oral Dose: two tablets twice daily |
| Verdiperstat | DRUG | Drug: Verdiperstat Administration: Oral Dose: 600mg twice daily |
Inclusion Criteria: * No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683). Exclusion Criteria: * The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). 1. Parti...